Indication: Vaginal dryness

Source: British Menopause Society Annual Meeting, July 2003

Research: The aim of the study was to evaluate the efficacy and safety of Promensil versus placebo on endometrial thickening, uterine blood flow to the uterus and the vaginal maturation index (VMI), a measure of normal functioning of the membrane lining the vagina. A prospective randomized, double-blind, placebo-controlled, cross-over trial with two eight-week phases was conducted. Twenty-nine women, aged 45 to 65, received either 80 mg of Promensil daily or placebo for the first treatment phase of eight weeks, followed by a two-week washout on placebo and an additional eight weeks on the reverse treatment.

Results: At the conclusion of the two eight-week phases, there was no in­crease in endometrial thickening for either the Promensil or placebo groups, but the Promensil group did show significant improvement in VMI compared to placebo.